氯沙坦预防肿瘤诱导的听力损失并增强NF2神经鞘瘤 rodent 模型的放疗疗效
在NF2小鼠模型中,氯沙坦通过减少神经炎症性IL-6/STAT3信号、正常化肿瘤血管和减轻神经水肿来改善听力并增强放疗疗效。患者样本分析显示IL-6/STAT3信号与听力功能负相关,回顾性分析提示血管紧张素受体阻滞剂可阻止VS诱导的听力损失进展。
要点
- 氯沙坦可减少NF2小鼠肿瘤微环境纤维化并预防听力损失。
- 氯沙坦正常化肿瘤血管、减轻神经水肿并增强放疗疗效。
- 回顾性分析提示ARB类药物可能延缓VS患者听力损失进展。
核心结论
- 氯沙坦通过靶向肿瘤微环境纤维化预防NF2相关听力损失并增强放疗疗效,为前瞻性临床试验提供依据。
研究设计与样本
- 使用NF2小鼠模型进行氯沙坦治疗实验,并结合患者样本、离体耳蜗培养和回顾性分析。
主要发现
- 氯沙坦减少神经炎症性IL-6/STAT3信号并预防听力损失。
- 氯沙坦正常化肿瘤血管并减轻神经水肿。
- 氯沙坦增加氧输送并增强放疗疗效。
- 患者样本中IL-6/STAT3信号与听力功能负相关。
- 肿瘤来源IL-6升高与耳蜗感觉细胞和神经元活力降低相关。
关键数值与推荐
- 回顾性分析显示接受血管紧张素受体阻滞剂的患者VS诱导的听力损失无进展, compared with 其他或未用降压药患者。
临床怎么用
- 氯沙坦可能作为NF2患者预防听力损失和增强放疗的潜在治疗选择。
- 需前瞻性临床试验验证氯沙坦在VS患者中的疗效。
局限性
- 回顾性分析存在固有局限,需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hearing loss is one of the most common symptoms of neurofibromatosis type 2 (NF2) caused by vestibular schwannomas (VSs). Fibrosis in the VS tumor microenvironment (TME) is associated with hearing loss in patients with NF2. We hypothesized that reducing the fibrosis using losartan, an FDA-approved antihypertensive drug that blocks fibrotic and inflammatory signaling, could improve hearing. Using NF2 mouse models, we found that losartan treatment normalized the TME by (i) reducing neuroinflammatory IL-6/STAT3 signaling and preventing hearing loss, (ii) normalizing tumor vasculature and alleviating neuro-edema, and (iii) increasing oxygen delivery and enhancing efficacy of radiation therapy. In preparation to translate these exciting findings into the clinic, we used patient samples and data and demonstrated that IL-6/STAT3 signaling inversely associated with hearing function, that elevated production of tumor-derived IL-6 was associated with reduced viability of cochlear sensory cells and neurons in ex vivo organotypic cochlear cultures, and that patients receiving angiotensin receptor blockers have no progression in VS-induced hearing loss compared with patients on other or no antihypertensives based on a retrospective analysis of patients with VS and hypertension. Our study provides the rationale and critical data for a prospective clinical trial of losartan in patients with VS.
引用
- Wu L, Vasilijic S, Sun Y, et al. Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci Transl Med. 2021. PMID: 34261799. doi:10.1126/scitranslmed.abd4816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。